###begin article-title 0
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 39 45 <span type="species:ncbi:9606">humans</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 206 212 <span type="species:ncbi:9606">humans</span>
###xml 229 233 <span type="species:ncbi:10116">rats</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
Studies in rodents and some studies in humans have shown that conjugated linoleic acid (CLA), especially its trans-10, cis-12 isomer, reduces body fat content. However, some but not all studies in mice and humans (though none in rats) have found that CLA promotes insulin resistance. The molecular mechanisms responsible for these effects are unclear, and there are conflicting reports on the effects of CLA on peroxisomal proliferator-activated receptor-gamma (PPARgamma) activation and expression. We have conducted three experiments with CLA in obese mice over three weeks, and one over eleven weeks. We have also investigated the effects of CLA isomers in PPARgamma and PPARalpha reporter gene assays.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 52 55 52 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 110 112 110 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 116 118 116 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 330 335 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 340 343 336 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 835 840 827 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 845 848 837 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 877 880 869 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 884 889 876 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
Inclusion of CLA or CLA enriched with its trans-10, cis-12 isomer in the diet of female genetically obese (lepob/lepob) mice for up to eleven weeks reduced body weight gain and white fat pad weight. After two weeks, in contrast to beneficial effects obtained with the PPARgamma agonist rosiglitazone, CLA or CLA enriched with its trans-10, cis-12 isomer raised fasting blood glucose and plasma insulin concentrations, and exacerbated glucose tolerance. After 10 weeks, however, CLA had beneficial effects on glucose and insulin concentrations. At this time, CLA had no effect on the plasma TNFalpha concentration, but it markedly reduced the plasma adiponectin concentration. CLA and CLA enriched with either isomer raised the plasma triglyceride concentration during the first three weeks, but not subsequently. CLA enriched with its trans-10, cis-12 isomer, but not with its cis-9, trans-11 isomer, stimulated PPARgamma-mediated reporter gene activity; both isomers stimulated PPARalpha-mediated reporter gene activity.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 77 79 77 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 263 268 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 273 276 265 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
CLA initially decreased but subsequently increased insulin sensitivity in lepob/lepob mice. Activation of both PPARgamma and PPARalpha may contribute to the improvement in insulin sensitivity. In the short term, however, another mechanism, activated primarily by trans-10, cis-12-CLA, which probably leads to reduced adipocyte number and consequently reduced plasma adiponectin concentration, may decrease insulin sensitivity.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 114 117 114 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 121 124 121 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 184 187 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 228 231 228 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
The term conjugated linoleic acid (CLA) refers to a mixture of positional and geometric isomers of linoleic acid (cis-9, cis-12-octadienoic acid). The major components of CLA, are the cis-9, trans-11 (c9, t11) and the trans-10, cis-12 (t10, c12) isomers, both of which have biological activities. The t10, c12-isomer is the one primarily responsible for the effects of CLA on weight gain and insulin sensitivity. The CLA used in the present study contains these isomers in roughly equal proportions.
###end p 9
###begin p 10
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 156 160 <span type="species:ncbi:10116">rats</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 223 229 <span type="species:ncbi:9606">humans</span>
###xml 462 466 <span type="species:ncbi:10116">rats</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
###xml 596 602 <span type="species:ncbi:9606">humans</span>
CLA may be of benefit in cancer, atherosclerosis and possibly some disorders of the immune system. In addition, it reduces weight gain and fat accretion in rats and mice. Some studies have found that CLA causes fat loss in humans [1-4], and two studies have shown weight loss[2,5], but another did not find any significant effect of CLA on body composition or body weight [6]. More marked effects of CLA on body weight and body composition have been obtained in rats and especially mice, possibly because the rate of energy expenditure relative to energy stores is much higher in rodents than in humans.
###end p 10
###begin p 11
###xml 144 146 144 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 150 152 150 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 491 493 491 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fa</sup>
###xml 488 493 488 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>fa</sup></italic>
###xml 497 500 497 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fa </sup>
###xml 494 500 494 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>fa </sup></italic>
###xml 529 531 529 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fa</sup>
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>fa</sup></italic>
###xml 535 538 535 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">fa </sup>
###xml 532 538 532 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>fa </sup></italic>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 723 725 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 828 830 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 285 291 <span type="species:ncbi:9606">humans</span>
###xml 538 542 <span type="species:ncbi:10116">rats</span>
###xml 704 708 <span type="species:ncbi:10090">mice</span>
###xml 717 721 <span type="species:ncbi:10116">rats</span>
###xml 805 809 <span type="species:ncbi:10090">mice</span>
###xml 822 826 <span type="species:ncbi:10116">rats</span>
In previous studies, CLA or t10, c12-CLA has exacerbated glucose tolerance and raised plasma insulin levels in normal and genetically obese (lepob/lepob) mice, despite causing weight loss [7-10]. Both t10, c12-CLA and c9, t11-CLA have also been reported to cause insulin resistance in humans [11-13], although in other studies neither CLA nor its major isomers affected insulin resistance significantly [14-17]. By contrast, CLA or t10, c12-CLA improved glucose tolerance in Zucker fatty lepfa/lepfa and Zucker diabetic fatty lepfa/lepfa rats [18-21]. One difference between the rodent species is that peroxisomal proliferator-activated receptor (PPAR)alpha-regulated genes are more responsive to CLA in mice than in rats [22], but this would be expected to correlate with improved insulin sensitivity in mice rather than rats [23].
###end p 11
###begin p 12
###xml 235 237 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 492 494 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 567 569 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 570 572 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 622 624 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 660 662 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 663 665 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 761 763 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 826 828 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 932 934 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 935 937 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 938 940 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 941 943 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 157 162 <span type="species:ncbi:10090">mouse</span>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 755 759 <span type="species:ncbi:10116">rats</span>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
###xml 900 904 <span type="species:ncbi:10090">mice</span>
By contrast with this result for PPARalpha knockout mice, at least one response to CLA depends on expression of PPARgamma: the beneficial effect of CLA in a mouse model of colitis was absent in mice that lacked PPARgamma in the colon [24]. In view of the variety of reports of CLA's effects on PPARgamma activity and expression, it is possible that PPARgamma responses may vary between species; the different proportions of isomers in the CLA used in different studies may also be important [25]. Some reports describe activation of PPARgamma by CLA or t10, c12-CLA [18,33]; others describe little or no agonist activity [10], but antagonism of rosiglitazone [25,27]. One report describes increased expression of PPARgamma mRNA in white adipose tissue of rats [28] and another describes increased expression in liver of mice [10], but studies in isolated adipocytes or of adipose tissue from treated mice show decreased expression [25,27,29,30].
###end p 12
###begin p 13
###xml 634 635 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 723 725 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 737 739 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 812 814 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 576 580 <span type="species:ncbi:10090">mice</span>
###xml 717 721 <span type="species:ncbi:10116">rats</span>
###xml 731 735 <span type="species:ncbi:10090">mice</span>
###xml 793 798 <span type="species:ncbi:10090">mouse</span>
Since PPARgamma agonists increase insulin sensitivity but promote adipogenesis, decreased activity of PPARgamma in adipose tissue could explain why CLA reduces obesity but increases insulin resistance. Various other mechanisms have also been suggested to explain why CLA exacerbates insulin sensitivity despite causing loss of fat. One of these is increased expression of tumour necrosis factor (TNF)alpha, since TNFalpha is associated with apoptosis of adipocytes but causes insulin resistance. TNFalpha mRNA levels were markedly increased in isolated adipocytes from normal mice that had been fed on CLA for as little as four days [8]. Surprisingly however, serum TNFalpha levels were reduced by CLA in both normal rats [31] and mice [32]. Moreover CLA reduced the expression of TNFalpha in mouse macrophages [33].
###end p 13
###begin p 14
###xml 154 156 154 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db</sup>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db</sup></italic>
###xml 160 163 160 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db </sup>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db </sup></italic>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 484 486 484 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db</sup>
###xml 481 486 481 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db</sup></italic>
###xml 490 493 490 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db </sup>
###xml 487 493 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db </sup></italic>
###xml 738 740 735 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 735 740 732 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 744 747 741 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 741 747 738 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 747 751 <span type="species:ncbi:10090">mice</span>
Although most studies in mice have found that CLA exacerbates glucose tolerance and raises the plasma insulin concentration, in one study treatment of lepdb/lepdb mice with CLA for eleven weeks improved glucose tolerance and reduced plasma insulin concentration during the glucose tolerance test, indicating improved insulin sensitivity. Treatment for five weeks also improved glucose tolerance but plasma insulin was raised [34]. It is sometimes difficult to interpret studies in lepdb/lepdb mice because beta-cell failure as well as insulin resistance affects glucose homeostasis, and glycosuria can cause weight loss. Therefore, to investigate the effect of CLA on glucose homeostasis further, we have conducted four experiments in lepob/lepob mice. We have included rosiglitazone as a comparator in one experiment and compared the effects of t10, c12- and c9, t11-enriched CLA with CLA in another experiment. The first three experiments were over 22 days, whereas the fourth was extended to eleven weeks and included measurements of plasma TNFalpha and adiponectin. An intriguing finding is that whereas CLA initially exacerbated glucose tolerance and raised the plasma insulin level, after ten weeks it began to improve glucose tolerance and lower the plasma insulin levels.
###end p 14
###begin p 15
We also describe activation of PPARgamma by t10, c12 but not by c9, t11-CLA, whereas PPARalpha was activated by both isomers.
###end p 15
###begin title 16
Results
###end title 16
###begin title 17
Weight gain
###end title 17
###begin p 18
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 199 203 <span type="species:ncbi:10090">Mice</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
Inclusion of CLA in the diet of genetically obese (lepob/lepob) mice reduced their body weight, or weight gain compared to mice fed on a diet containing a similar amount of sunflower oil (Figure 1). Mice fed on chow supplemented with sunflower oil gained weight at the same rate as mice fed on chow alone (Figure 1b). The effect of CLA on weight gain appears to be primarily due to t10, c12-CLA, since CLA enriched to 90% with this isomer had more effect on weight gain than CLA containing 50% t10, c12-CLA and 50% c9, t11-CLA (Figure 1c). CLA that was enriched to 90% with the c9, t11 isomer had only a small effect on weight gain, and this may have been due to the 10% t10, c12-CLA. Food intake was measured over two days in experiment 4 and was not reduced by CLA (food intake per group: control, 33.1 and 37.5 g; CLA 10 g/kg diet, 35.1, 43.4 g; CLA 25 g/kg diet, 39.9, 39.6). Rosiglitazone (10 mg/kg diet) reduced body weight (Figure 1a) but to a lesser extent than CLA (15 g/kg diet).
###end p 18
###begin p 19
###xml 460 462 430 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 472 474 442 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 485 487 455 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
Weight gain in mice fed on diets that contained (doses per kg diet) (a) experiment 1: sunflower oil (●, 15 g), rosiglitazone (◇,10 mg), CLA (▲, 15 g); (b) experiment 2: chow only (o), sunflower oil (●, 25 g), CLA (▲, 25 g); (c) experiment 3: sunflower oil (●, 25 g), CLA (▲, 25 g), t10, c12-CLA (big up tri, open, 25 g), c9, t11-CLA (big dn tri, open, 25 g); (d) experiment 4: sunflower oil (●, 25 g), CLA (10 g) plus sunflower oil (15 g) (■), CLA (▲, 25 g). *P < 0.05; **P < 0.01: ***P < 0.001 compared to sunflower oil group.
###end p 19
###begin title 20
Tissue weights and body length
###end title 20
###begin p 21
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
The weight of the parametrial white fat pads was reduced by CLA and by CLA enriched with t10, c12- but not c9, t11-CLA (Tables 1 and 2). The weight of the interscapular brown fat pad was reduced by CLA in experiment 4 (Table 2) but not in experiment 3 (Table 1). This may be because experiment 4 lasted for 11 weeks, whereas experiment 3 lasted for only 3 weeks and the control brown fat pad was more than three times heavier at the end of experiment 4 than at the end of experiment 3, presumably due primarily to its lipid content.
###end p 21
###begin p 22
###xml 96 100 <span type="species:ncbi:10090">mice</span>
Terminal tissue weights and NEFA levels in experiment 3. NEFA levels were measured in 5h-fasted mice on day 13. Termination was on day 22. Supplements were included in the diet at concentrations of 25 g/kg.
###end p 22
###begin p 23
+ P < 0.001; n = 6
###end p 23
###begin p 24
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
Terminal tissue weights and plasma hormones and NEFA levels in experiment 4. NEFA levels were determined in 5h-fasted mice on the days shown. Other measurements were in fed mice on day 77.
###end p 24
###begin p 25
* P < 0.05; + P < 0.001; n = 6
###end p 25
###begin p 26
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
Liver weight was increased by CLA and by CLA enriched with either isomer, c9, t11-enriched CLA having the smallest effect. The weight of the pancreas was unaffected by all treatments (Tables 1 and 2). Others have reported that t10, c12- and c9, t11-CLA increase liver weight in lean mice, the effect of the t10, c12 isomer being associated with increased liver lipid [35].
###end p 26
###begin p 27
###xml 38 39 38 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Body length was reduced by CLA (Table 2).
###end p 27
###begin title 28
Glucose tolerance
###end title 28
###begin p 29
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2d</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
Rosiglitazone lowered fasting blood glucose, improved glucose tolerance (Figure 2a) and reduced the area under the glucose tolerance curve (Figure 3a). Two weeks treatment with CLA or with CLA enriched with t10, c12-CLA raised fasting blood glucose, exacerbated glucose tolerance (Figures 2b to 2d) and increased the area under the glucose tolerance curve (Figures 3b to 3d) compared to the sunflower oil and chow alone diets. CLA-enriched with c9, t11-CLA had no effect (Figures 2c and 3c).
###end p 29
###begin p 30
Oral glucose tolerance. Symbols are the same as in Figure 1 and again (a) is experiment 1, (b) is experiment 2 and (c) is experiment 3. (d), (e) and (f) are oral glucose tolerance curve on days 14, 35 and 70 for experiment 4.
###end p 30
###begin p 31
###xml 152 154 152 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 164 166 164 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 177 179 177 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Areas under the glucose tolerance curves shown in Figure 2. Panel (d) shows areas from Figure 2 (d), (e) and (f). Doses of CLA are shown as g/kg diet. *P < 0.05; **P < 0.01: ***P < 0.001 compared to sunflower oil group.
###end p 31
###begin p 32
###xml 117 122 117 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2d, e</xref>
###xml 124 129 124 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d, e</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2f</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3d</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
After five weeks of treatment the higher dose of CLA raised glucose levels less than it had after two weeks (Figures 2d, e; 3d, e), and after 10 weeks this dose actually improved glucose tolerance (Figure 2f) and reduced the area under the glucose tolerance curve (Figure 3d). Its effect was similar to that of rosiglitazone over two weeks in experiment 1 (Figures 2a and 3a). The lower dose reduced the peak glucose level after 10 weeks, but it did not reduce the area under the glucose tolerance curve significantly.
###end p 32
###begin title 33
Insulin
###end title 33
###begin p 34
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
The improvement in glucose tolerance in response to rosiglitazone was associated with a reduction in the fasting plasma insulin level, but rosiglitazone did not reduce the terminal fasting insulin level (Figure 4a). The exacerbations of glucose tolerance in response to two weeks treatment with CLA and CLA enriched with t10, c12-CLA were associated with increases in the fasting plasma insulin level. CLA enriched with c9, t11-CLA did not alter the fasting insulin level on the day that it showed no effect on glucose tolerance. However, c9, t11-enriched CLA increased the plasma insulin level in fed mice on day 21 (Figure 4c).
###end p 34
###begin p 35
###xml 394 396 394 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 406 408 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 419 421 419 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Plasma insulin values from (a) experiment 1, (b) experiment 2, (c) experiment 3, and (d) experiment 4. Doses are described in Methods and the legend to Figure 1. In panel (d) the does of CLA are in g/kg diet. Day 13 or 14, day 35 and day 70 values are following a 4.5 h fast; day 22 values are following a 16 h fast; and day 21 values are for fed animals. Doses of CLA are shown as g/kg diet. *P < 0.05; **P < 0.01: ***P < 0.001 compared to sunflower oil group.
###end p 35
###begin p 36
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4d</xref>
After five weeks both doses of CLA still raised the fasting plasma insulin level, but after ten weeks, both doses reduced the plasma insulin level compared to the control group (Figure 4d).
###end p 36
###begin title 37
Insulin resistance
###end title 37
###begin p 38
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 518 519 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 243 249 <span type="species:ncbi:9606">humans</span>
A useful indicator of insulin resistance can be obtained by multiplying values for fasting blood glucose and plasma insulin concentrations [36]. This is analogous to homeostatic model assessment (HOMA), which has been developed for studies in humans, although the full version, which originally involved dividing the product of glucose (mM) and insulin (mU/ml) concentrations by 22.5 is not suitable for studies in rodents [37]. By multiplying fasting blood glucose (mM) by plasma insulin (nM) we illustrate in Figure 5 how CLA initially exacerbated but subsequently improved insulin resistance.
###end p 38
###begin p 39
Effect of CLA on insulin sensitivity in experiment 4. The insulin sensitivity index was determined by multiplying the fasting blood glucose concentration (Figure 2d, e, f, 0 min) by the fasting plasma insulin concentration (Figure 4d).
###end p 39
###begin title 40
Triglycerides and fatty acids
###end title 40
###begin p 41
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6c</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6d</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6c</xref>
CLA raised the fasting triglyceride level in experiments 1 to 3 (Figures 6a to 6c), but in experiment 4 the only statistically significant effect was an increase elicited by the lower dose after two weeks (Figure 6d). CLA enriched with t10, c12-CLA had a similar or greater effect than CLA. Surprisingly on day 13 c9, t11-CLA, but not CLA or t10, c12-CLA caused a significant increase in the plasma triglyceride level, although c9, t11-CLA did not have a significant effect compared to CLA (Figure 6c).
###end p 41
###begin p 42
###xml 399 401 399 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 411 413 411 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 424 426 424 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Plasma triglyceride values from (a) experiment 1, (b) experiment 2, (c) experiment 3, and (d) experiment 4. Doses are described in Methods and the legend to Figure 1. In panel (d) the does of CLA are in g/kg diet. Day 13 or 14, day 35 and day 70 values are following a 4.5 h fast; day 22 values are following a 16 h fast; and day 21 values are for fed animals. Doses of CLA are shown as g/kg diet. *P < 0.05; **P < 0.01: ***P < 0.001 compared to sunflower oil group.
###end p 42
###begin p 43
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
CLA and isomer-enriched CLAs had no effect on the fasting plasma non-esterified fatty acid (NEFA) concentration in experiment 3 (Table 1), and CLA had no effect after two and five weeks in experiment 4 (Table 2). After ten weeks, however, the lower dose of CLA raised the plasma concentration of NEFA, whereas the higher dose lowered it (Table 2).
###end p 43
###begin title 44
TNFalpha and adiponectin
###end title 44
###begin p 45
###xml 153 154 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
After ten weeks CLA had no effect on the plasma TNFalpha concentration. The plasma adiponectin concentration, by contrast, was markedly decreased (Table 2).
###end p 45
###begin title 46
PPAR activation
###end title 46
###begin p 47
###xml 136 138 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 309 311 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7b</xref>
CLA enriched with t10, c12-CLA (50 and 100 muM), but not with c9, t11-CLA, stimulated PPARgamma-mediated reporter gene activity (Figure 7a). In contrast, both CLA isomers (100 muM) elicited a significant increase in PPARalpha-mediated reporter gene expression, and c9, t11-CLA was effective at 10 muM (Figure 7b).
###end p 47
###begin p 48
###xml 52 53 52 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 71 72 67 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 230 231 214 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 255 256 235 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 298 299 278 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 308 309 288 289 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 620 622 600 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 636 638 616 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Effect of the c9, t11 and t10, c12-enriched CLA on (a) PPARgamma- and (b) PPARalpha mediated gene expression. Cos-7 cells were transiently transfected with the plasmids pPPRE3TK-luc, pRLTK, pRSV/hRXRalpha and pcDNA3/hPPARgamma 1 (a) or pcDNA3/hPPARalpha (b). Transfected cells were treated for 46 (a) or 24 (b) hours. Cell extracts were assayed for firefly and renilla luciferase activity. Reporter gene activity was determined by normalising firefly luciferase activity against renilla luciferase activity. The CLA isomers were prepared in 0.1% DMSO so that each of the stated isomers was at the given concentration. * P < 0.05 and ** P < 0.01; n = 6.
###end p 48
###begin title 49
Discussion
###end title 49
###begin title 50
Physiology
###end title 50
###begin p 51
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 494 496 494 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db</sup>
###xml 491 496 491 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db</sup></italic>
###xml 500 503 500 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db </sup>
###xml 497 503 497 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db </sup></italic>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 534 535 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 910 912 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 973 975 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 86 90 <span type="species:ncbi:10116">rats</span>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 399 403 <span type="species:ncbi:10116">rats</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 503 507 <span type="species:ncbi:10090">mice</span>
###xml 544 550 <span type="species:ncbi:9606">humans</span>
###xml 780 783 <span type="species:ncbi:9606">men</span>
A number of studies have found that CLA reduces weight gain and fat accretion in both rats and mice. Those that have failed to show such effects are generally those that have used low levels of CLA or CLA that contained low concentrations of t10, c12-CLA [6]. Studies disagree, however, as to whether CLA improves or exacerbates glucose tolerance and insulin resistance in these species: studies in rats show improvements [18-21], whereas studies in mice, with the exception of one study in lepdb/lepdb mice [34], show exacerbations [7-10]. In humans, several studies have shown a loss of fat [1-4], but doubts have been raised about the use of CLA for the treatment of obesity by reports that both t10, c12-CLA and c9, t11-CLA exacerbated insulin resistance in abdominally obese men [11-13], and that t10, c12- (but not c9, t11-CLA) reduced the HDL cholesterol concentration or the HDL:LDL cholesterol ratio [11,12,14]. These are by no means consistent findings, however [13-17].
###end p 51
###begin p 52
###xml 277 279 277 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 283 285 283 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 395 398 395 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 392 398 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 986 988 986 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 983 988 983 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 992 995 992 995 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 989 995 989 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 398 402 <span type="species:ncbi:10090">mice</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 995 999 <span type="species:ncbi:10090">mice</span>
Our study raises the possibility that an initial exacerbation of glucose tolerance, apparently due to insulin resistance, might, after prolonged treatment with a high dose of CLA, be followed by improved insulin sensitivity and glucose tolerance. We used genetically obese (lepob/lepob) mice as our model of insulin resistance. There is only one previous report of the effect of CLA in lepob/lepob mice [9]. In agreement with other studies in rodents, we found that CLA reduced weight gain and perigenital fat pad weight, and that this effect appeared to be produced by the t10, c12- rather than the c9, t11-isomer. We also found, like other studies in mice, that glucose tolerance was initially exacerbated and the plasma insulin concentration was raised. Again, these effects were primarily due to the t10, c12-isomer. However, in our last experiment we found that after ten weeks glucose tolerance improved and the fasting plasma insulin concentration was reduced by treatment of lepob/lepob mice with CLA. These benefits were achieved faster with the higher (25 g/kg diet, including 40% t10, c12-CLA) than the lower dose (10 g/kg diet) of CLA.
###end p 52
###begin p 53
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 98 100 98 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db</sup>
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db</sup></italic>
###xml 104 107 104 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db </sup>
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db </sup></italic>
###xml 234 239 234 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 294 296 294 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db</sup>
###xml 291 296 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db</sup></italic>
###xml 300 303 300 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db </sup>
###xml 297 303 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db </sup></italic>
###xml 621 623 621 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 618 623 618 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 627 630 627 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 624 630 624 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 729 730 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1032 1033 1032 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1034 1035 1034 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1456 1458 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
###xml 1026 1030 <span type="species:ncbi:10090">mice</span>
###xml 1125 1129 <span type="species:ncbi:10090">mice</span>
###xml 1294 1300 <span type="species:ncbi:9606">humans</span>
Our results are similar to those of Hamura et al [34], insofar as they found that treatment of lepdb/lepdb mice with CLA for eleven weeks improved glucose tolerance and lowered insulin levels during the glucose tolerance test. Hamura et al. found that glucose tolerance was also improved in lepdb/lepdb mice after five weeks of treatment, but this was apparently due to increased insulin secretion rather than improved insulin sensitivity. It is not clear why others have not also found improved glucose tolerance and reduced insulin levels following prolonged treatment of mice with CLA. In the one previous study in lepob/lepob mice, the dose of t10, c12-CLA was only about 5.9 g/kg diet and treatment was for only four weeks [9]. A study in lean C57Bl/6J mice similarly used a dose of 4 g/kg diet of t10, c12-CLA for four weeks [10]. Other studies lasted for twelve weeks and eight months, however. The dose of CLA was only 10 g/kg diet in both studies and neither was conducted in exceptionally obese or insulin resistant mice [7,8]. We therefore suggest that improved insulin sensitivity is most likely to be found when mice are initially markedly obese and insulin resistant, and when treatment is prolonged and results in a major loss of adipose tissue. The relevance of our findings to humans is unclear, but it is interesting that in one 12 month study plasma glucose was raised after two weeks treatment with CLA, but not at any subsequent time [16].
###end p 53
###begin p 54
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 776 777 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 787 792 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 877 879 877 879 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db</sup>
###xml 874 879 874 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db</sup></italic>
###xml 883 886 883 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db </sup>
###xml 880 886 880 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>db </sup></italic>
###xml 1320 1322 1320 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1323 1325 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1326 1328 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
###xml 1312 1318 <span type="species:ncbi:9606">humans</span>
After ten weeks the higher dose of CLA lowered the plasma fasting non-esterified fatty acid concentration, which is consistent with improved insulin sensitivity (Table 2). The lower dose raised the NEFA concentration at this time, despite apparently improving insulin sensitivity, even though it did not raise the NEFA concentration at earlier times when glucose tolerance was reduced and plasma insulin levels were raised. This paradox seems to be largely a consequence of the low control NEFA concentration after ten weeks: the highest NEFA level in the low dose CLA group was after five weeks of treatment and it seems possible that the NEFA concentration in the low dose group would have fallen with further treatment, just as it was falling in the high dose group (Table 2). Hamura et al. [34] found that after twelve weeks CLA reduced the plasma NEFA concentration in lepdb/lepdb mice, suggesting that insulin sensitivity was improved. After six weeks, however, CLA raised the NEFA concentration, suggesting that CLA exacerbated insulin sensitivity at this time. The elevated plasma NEFA concentration may have been partly responsible for the elevated plasma insulin and improved glucose tolerance after six weeks in their study. CLA and its major isomers have little or no effect on plasma NEFA levels in humans [11,12,14].
###end p 54
###begin title 55
Mechanism
###end title 55
###begin p 56
No single mechanism has been identified that can account for the various effects of CLA on lipid and carbohydrate metabolism, let alone its anticarcinogenic and immunomodulatory activities. In part this is because CLA is a mixture of isomers, each with its own balance of activities. The activities of even the most active isomer, t10, c12-CLA, cannot, however, be pinned down to a single mechanism.
###end p 56
###begin p 57
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 195 197 195 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 201 204 201 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 198 204 198 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
We can first rule out any possibility that responses to CLA in our experiments were mediated by a fall in leptin levels as has been suggested by others [8], because our study was conducted in lepob/lepob mice. In any event, when fat loss is achieved by reducing energy intake, insulin action and glucose tolerance improve despite a reduction in the plasma leptin concentration.
###end p 57
###begin p 58
###xml 129 131 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 200 202 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 319 321 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 404 406 396 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 401 406 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 410 413 402 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 407 413 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 436 438 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 443 445 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 484 485 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
Antagonism of PPARgamma by t10, c12-CLA has been suggested to contribute to both decreased adipogenesis and insulin sensitivity [38]. A recent report that c9, t11-CLA exacerbates insulin sensitivity [12] is consistent with a report that it too antagonises PPARgamma, albeit a little less effectively than t10, c12-CLA [25]. We found little evidence that c9, t11-CLA exacerbates insulin sensitivity in lepob/lepob mice, however (Figures 3c and 4c), and others have reported no effect [9].
###end p 58
###begin p 59
###xml 182 184 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 262 264 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 265 267 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 441 443 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10116">rats</span>
Some workers favour the hypothesis that t10, c12-CLA decreases adipogenesis and insulin sensitivity by a mechanism that involves decreased expression of PPARgamma in adipose tissue [38]. Since PPARgamma agonists increase PPARgamma expression in some situations [39,40], antagonism of PPARgamma might decrease PPARgamma expression. By contrast with mice, however, in rats CLA increases both PPARgamma mRNA expression and insulin sensitivity [28]. Thus it is possible that CLA activates one mechanism that decreases and another that increases insulin sensitivity, and that PPARgamma expression reflects the balance of these forces, rather than having a causal role.
###end p 59
###begin p 60
###xml 136 138 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 139 141 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 301 303 289 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 298 303 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 307 310 295 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 304 310 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
In any event, our results do not support antagonism of PPARgamma as a mechanism of action of CLA. In agreement with some other workers [18,33], we find that t10, c12-CLA, but not c9, t11-CLA activates PPARgamma. Activation of PPARgamma might contribute to the improvement in insulin sensitivity in lepob/lepob mice following prolonged treatment with CLA.
###end p 60
###begin p 61
###xml 394 396 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 397 399 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
Activation of PPARalpha might also contribute to improved insulin sensitivity. t10, c12-CLA was more potent as an activator of PPARalpha than of PPARgamma in the particular assays that we used, although it is inappropriate to make precise comparisons of potency in view of the different plasmids, their levels and other differences between the two assays. In contrast to some previous reports [10,41], t10, c12-CLA was, if anything, more potent than c9, t11-CLA as an activator of PPARalpha. Nevertheless, c9, t11-CLA was sufficiently effective to raise the possibility that it contributed to the improvement in insulin sensitivity due to the prolonged treatment with CLA.
###end p 61
###begin p 62
###xml 199 201 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 375 377 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 503 505 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 506 508 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 576 578 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 579 581 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 681 683 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
Activation of PPARalpha and peroxisomal proliferation might contribute to the increased liver weight in c9, t11-CLA-treated mice, steatosis also playing a role, at least in the case of t10, c12-CLA [10]. Activation of PPARalpha does not, however, appear to have a major role in the anti-obesity effect of CLA, because CLA reduced body fat content in PPARalpha knockout mice [42]. Moreover, some investigators have found that c9, t11-CLA is more effective than t10, c12-CLA as an activator of PPARalpha [10,41]. Other workers have shown that CLA also activates PPARbeta/delta [10,41], but the effect was small in one these studies and c9, t11-CLA was more potent than t10, c12-CLA [10].
###end p 62
###begin p 63
###xml 457 459 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 585 587 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1000 1002 992 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 1006 1009 998 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 1288 1290 1280 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1291 1293 1283 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1329 1331 1321 1323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 1326 1331 1318 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 1335 1338 1327 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 1332 1338 1324 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 1433 1434 1425 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1477 1486 1469 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">increase </italic>
###xml 1627 1629 1619 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
###xml 1009 1013 <span type="species:ncbi:10090">mice</span>
###xml 1253 1257 <span type="species:ncbi:10090">mice</span>
###xml 1338 1342 <span type="species:ncbi:10090">mice</span>
###xml 1537 1541 <span type="species:ncbi:10116">rats</span>
###xml 1706 1710 <span type="species:ncbi:10116">rats</span>
We measured plasma TNFalpha and adiponectin concentrations following prolonged treatment with CLA. Neither hormone contributed to the improved insulin sensitivity at this time: the plasma TNFalpha concentration was unchanged by CLA, and the plasma adiponectin concentration was reduced rather than increased. Other investigators have reported that t10, c12-CLA but not c9, t11-CLA reduces the level of adiponectin mRNA in white adipose tissue of lean mice [35]. Since adiponectin is released primarily from adipocytes but plasma levels are low in obesity and increased by weight loss [43], the marked reduction in plasma adiponectin in the CLA-treated mice is consistent with their having less, rather than smaller, adipocytes. This is in turn consistent with the view that the anti-obesity effect of CLA and the initial decrease in insulin sensitivity is due to apoptosis of adipocytes. Decreased fat cell number may also account for the tendency of CLA to increase plasma triglyceride levels in lepob/lepob mice, the remaining fat cells being too full to accommodate the triglyceride released by cells that have undergone apoptosis. Other workers have reported that CLA reduces plasma triglyceride levels; but in some cases this reduction was in lean mice with less replete adipocytes [42,26], and in the one other study in lepob/lepob mice, it was an effect of c9, t11-CLA, which presumably causes little apoptosis of adipocytes [9]. Interestingly, CLA has been reported to increase plasma adiponectin levels in Zucker diabetic fatty rats, at the same time decreasing plasma triglycerides and improving insulin sensitivity [21]. We therefore suggest that the main effect of CLA in Zucker diabetic fatty rats is to reduce fat cell size, rather than to promote apoptosis and reduce fat cell number.
###end p 63
###begin title 64
Conclusions
###end title 64
###begin p 65
###xml 92 94 92 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Treatment with CLA initially decreased but subsequently increased insulin sensitivity in lepob/lepob mice. Activation of both PPARgamma and PPARalpha may contribute to the improvement in insulin sensitivity. In the short term, however, another mechanism, activated by t10, c12-CLA but not c9, t11-CLA, which probably leads to reduced adipocyte number and consequently plasma adiponectin concentration, may decrease insulin sensitivity.
###end p 65
###begin title 66
Methods
###end title 66
###begin title 67
Animals
###end title 67
###begin p 68
###xml 18 20 18 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob</sup>
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob</sup></italic>
###xml 24 27 24 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ob </sup>
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lep<sup>ob </sup></italic>
###xml 505 515 497 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum</italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 207 210 <span type="species:ncbi:10116">rat</span>
###xml 215 220 <span type="species:ncbi:10090">mouse</span>
###xml 367 371 <span type="species:ncbi:10090">mice</span>
###xml 521 525 <span type="species:ncbi:10090">mice</span>
Female C57Bl/6 lepob/lepob mice were obtained from Harlan Olac (Bicester, UK) and maintained at 23 +/- 1degreesC with lights on from 07:00 to 19:00 h. They were housed in plastic cages with bedding and fed 'rat and mouse standard diet' (Beekay Feed, B & K Universal Ltd., Hull, UK). Six days before the start of the studies they were allocated to treatment groups (6 mice per group), such that each group had a similar mean bodyweight. The CLA and other treatments were mixed with powdered diet and given ad libitum. The mice were killed by cervical dislocation in experiments 1 to 3; in experiment 4 they were anaesthetised with sodium pentobarbitone (Sagatal; 80 mg/kg, i.p.) and exsanguinated through an aortic catheter. All procedures were conducted in accordance with our Home Office, UK project licence under the Animals (Scientific Procedures) Act and as agreed by the University of Buckingham Ethical Review Board.
###end p 68
###begin title 69
Materials added to diets
###end title 69
###begin p 70
CLA (in acid form), including isomer-enriched CLA, and sunflower oil were provided by Loders Croklaan, Wormerveer, The Netherlands. The CLA used in experiments 1, 2 and 3 was Clarinoltrade mark A-60, containing 30% c9, t11-CLA and 31% t10, c12-CLA and 25% oleic acid. The CLA used in experiment 4 was Clarinoltrade mark A-80, containing 40% c9, t11-CLA and 40% t10, c12-CLA. Rosiglitazone was synthesised by Dextra Laboratories, Reading, Berks, UK.
###end p 70
###begin title 71
Experiment 1
###end title 71
###begin p 72
###xml 612 622 598 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum</italic>
###xml 30 34 <span type="species:ncbi:10090">mice</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
At the start of treatment the mice weighed 34.5 +/- 4.3 g (mean +/- S.D.). The treatment groups were high oleic (83.5%) sunflower oil (control; 15 g/kg diet); rosiglitazone (10 mg/kg diet) plus high oleic sunflower oil (15 g/kg diet); CLA (Clarinoltrade mark A-60: 15 g/kg diet). An oral glucose tolerance test was conducted after 14 days as described below. 30 min prior to giving glucose, when the mice had been fasted for 4.5 hours, blood (100 mul) was taken for the measurement of plasma insulin and triglycerides. Plasma insulin and triglycerides were also measured after 21 days when the mice were feeding ad libitum, and after 22 days when they had been fasted for 16 hours, immediately before termination of the experiment.
###end p 72
###begin title 73
Experiment 2
###end title 73
###begin p 74
###xml 34 38 <span type="species:ncbi:10090">mice</span>
At the start of the treatment the mice weighed 44.0 +/- 3.2 g (mean +/- S.D.). A group fed on powdered chow alone was included. The doses of CLA (Clarinoltrade mark A-60) and sunflower oil in the other two groups were increased to 25 g/kg diet. The oral glucose tolerance test and other measurements were carried out as described for experiment 1, except that the glucose tolerance test was one day earlier (i.e. after 13 days).
###end p 74
###begin title 75
Experiment 3
###end title 75
###begin p 76
###xml 30 34 <span type="species:ncbi:10090">mice</span>
At the start of treatment the mice weighed 34.1 +/- 2.1 g (mean +/- S.D.). The treatment groups were high oleic sunflower oil (25 g/kg diet); CLA (Clarinol trade mark A-60: 25 g/kg diet); CLA with the CLA component of Clarinol enriched to 90% with t10, c12-CLA (25 g/kg diet); similarly, CLA enriched to 90% with c9, t11-CLA (25 g/kg diet). The oral glucose tolerance test and other measurements were carried out as described for experiment 2. In addition, the plasma non-esterified fatty acid concentration was measured in the blood taken prior to the glucose tolerance test, and the liver, pancreas, parametrial white adipose tissue depot and interscapular brown adipose tissue depot were weighed at termination.
###end p 76
###begin title 77
Experiment 4
###end title 77
###begin p 78
###xml 30 34 <span type="species:ncbi:10090">mice</span>
At the start of treatment the mice weighed 31.6 +/- 3.8 g (mean +/- S.D.). The treatment groups were high oleate (as glyceride) sunflower oil (25 g/kg diet); CLA (Clarinol A80: 10 g/kg diet) plus high oleic sunflower oil (15g/kg diet); CLA (Clarinol A80: 25 g/kg diet). Oral glucose tolerance tests preceded by blood sampling for the measurement of triglycerides, insulin and non-esterified fatty acids were taken after 14, 35 and 70 days of treatment. After 77 days of treatment the animals were anaesthetised in the fed state and blood was taken from the thoracic aorta for the measurement of plasma TNFalpha and adiponectin. Tissues were weighed as in experiment 3. Body length was measured from the tip of the nose to the anus.
###end p 78
###begin title 79
Oral glucose tolerance tests
###end title 79
###begin p 80
###xml 143 147 <span type="species:ncbi:10090">mice</span>
In each experiment oral glucose tolerance was measured after 13 or 14 days. In experiment 4 it was also measured after five and ten weeks. The mice were fasted for five hours before being dosed with glucose (3 g/kg, p.o. in experiments 1 and 2; 2 g/kg, p.o. in experiments 3 and 4). Blood samples (20 mul) were taken from the tip of the tail after applying a local anaesthetic (lignocaine) and immediately before and 30, 60, 90, 120 and 180 min after dosing the glucose. They were mixed with haemolysis reagent and blood glucose was measured in duplicate using the Sigma Enzymatic (Trinder) colorimetric method and a SpectraMax 250 (Molecular Devices Corporation, Sunnyvale, CA, USA). Areas under the glucose tolerance curve (0-180 min) and other manipulations and analysis of the data were carried out using Prism software, version 3.0 (GraphPad Software Inc., San Diego, CA, USA).
###end p 80
###begin title 81
Other plasma analytes
###end title 81
###begin p 82
###xml 413 418 <span type="species:ncbi:10090">mouse</span>
Blood was collected into EDTA-coated microcuvettes (Sarstedt microcuvette, Aktiengsellschaft & Co., Nambrecht, Germany) for the measurement of plasma insulin, non-esterified fatty acids and triglycerides. Plasma was stored at -80degreesC. 5 mul plasma samples were assayed using kits for triglyceride (Sigma enzymatic colorimetric method), non-esterified fatty acids (Wako Chemicals, Neuss, Germany) and insulin (mouse standard; Crystal Chemistry Incorporated, Downers Grove, IL, USA).
###end p 82
###begin p 83
For the measurement of plasma TNFalpha (Linco; St Charles, MI, USA) and adiponectin (Biosource UK, Nivelles, Belgium), blood was taken into tubes containing 200 units of heparin and plasma was stored at -80degreesC.
###end p 83
###begin title 84
Plasmids for reporter gene assays
###end title 84
###begin p 85
###xml 1100 1103 1074 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlu</italic>
###xml 1109 1112 1083 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 1261 1269 1231 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 1387 1390 1345 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nru</italic>
###xml 1392 1395 1350 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 1428 1431 1386 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 1434 1437 1392 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bam</italic>
###xml 1524 1532 1482 1490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 1261 1268 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 1332 1337 <span type="species:ncbi:9606">human</span>
###xml 1524 1531 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
pRSV/hRXRalpha and pcDNA3/hPPARgamma1 were both obtained from Professor VKK Chatterjee (Addenbrooke's Hospital, Cambridge, UK). PPPRE3TK-luc was prepared by replacing the NF-kB enhancer element of pNF-kappaB-luc (Clontech) with a cassette of 3 PPAR Response Elements (PPREs). A double-stranded PPRE cassette was prepared using the 'Klenow fill-in' technique. An 113 bp oligonucleotide (PPRE3) 5'- GCATTCACGCGTCAAATATAGGCCATAGGTCATTCTCGAGCAAATATAGGCCATAGGTCATTCTCGAGCAAATATAGGCCATAGGTCAGATTCGATCAATATAGGCCATAGGTCACTCGAGGCAACAGATCTTACGCATG -3' containing a triplet of PPREs and appropriate restriction endonuclease sites was used as a template for synthesis of a second DNA strand. This was primed by PPRE3R, 5'-CATGCGTAAGATCTGTTGCC-3', which is complementary to the 3' region of PPRE3. 20 mul annealed PPRE3 and PPRE3R, 1.5 mul 2 mM dNTPs, 1 x Klenow Buffer and 5 units DNA Polymerase I (Klenow fragment), were incubated for 1 hour at 37degreesC and then 10 minutes at 75degreesC, purified by ethanol precipitation and resuspended in sterile water. The double-stranded PPRE cassette was digested with MluI and BglII and ligated into pNF-kappa B-luc that had been cleaved with the same restriction endonucleases. Ligated DNA was transformed into competent JM109, E. coli cells (Promega). pcDNA3/PPARalpha was prepared by removing the human PPARalpha cDNA insert from pUC18/hPPARalpha as a NruI/BamHI fragment and ligating it into EcoRV/BamHI cleaved pcDNA3.1(-) (Invitrogen). Ligated DNA was transformed into competent JM109, E. coli cells (Promega).
###end p 85
###begin title 86
PPARgamma and PPARalpha reporter gene assays
###end title 86
###begin p 87
###xml 171 172 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 370 372 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 1208 1210 1181 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 1600 1602 1558 1560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1501 1507 <span type="species:ncbi:9913">bovine</span>
###xml 1508 1512 <span type="species:ncbi:9913">calf</span>
Cos-7 cells (ECACC No. 87021302) were routinely cultured in DMEM containing 10% FCS, 2 mM L-Glutamine, 100 iu/ml penicillin and 100 mug/ml streptomycin at 37degreesC/5% CO2. Transient transfections were performed using LipofectAMINE as directed by the manufacturers (GibcoBRL). For the PPARgamma assay Cos-7 cells were plated in 24-well plates at a density of 0.375 x 105 cells/well. Cells were transfected in serum-free medium (DMEM containing 2 mM L-glutamine) with pPPRE3TK-luc, pRLTK, pRSV/hRXRalpha and pcDNA3/hPPARgamma 1 at concentrations of 0.4, 0.03, 0.02 and 0.02 mug/well, respectively. Five hours after transfection cells were fed with 250 mul/well of serum-free medium containing various concentrations (0-100 muM) of CLA (either the c9, t11 isomer or t10, c12 isomer prepared in 0.1% DMSO). Cell lysates were prepared after 46 hours using 100 mul 1 x passive lysis buffer (Promega) per well. Firefly and renilla luciferase activities were measured using a Dual Luciferase Assay kit (Promega), as described by the manufacturers. Measurements were performed on an MLX microtitre plate luminometer (Dynex). For the PPARalpha assay Cos-7 cells were plated in 24-well plates at a density of 0.5 x 105 cells/well. Cells were transfected in serum-free medium with pPPRE3TK-luc, pRLTK, pRSV/hRXRalpha and pcDNA3/hPPARalpha at concentrations of 0.4, 0.04, 0.03 and 0.03 mug/well, respectively. Five hours after transfection DMEM supplemented with 2 mM L-glutamine and 20% SBCS (charcoal-stripped bovine calf serum, Sigma) was added to the cells. Following 18 hours incubation at 37degreesC/5% CO2 the medium was removed and replaced with medium (DMEM supplemented with 2 mM L-glutamine and 10% SBCS) containing various concentrations (0-100 muM) of CLA enriched to 85% with the c9, t11 isomer or 81% with the t10, c12 isomer prepared in 0.1% DMSO. After 24 hours of treatment cell lysates were prepared and luciferase activity measured as described above.
###end p 87
###begin title 88
Statistics
###end title 88
###begin p 89
Data were analysed by one-way analysis of variance followed by LSD test with the sunflower oil treatment as the control. Means are of 6 values with SEM.
###end p 89
###begin title 90
Authors' contributions
###end title 90
###begin p 91
###xml 95 103 95 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 167 176 167 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
MC, LB, IM and MS devised the experiments. EW, MS and CS, supported by JO and SW conducted the in vivo experiments and analysed materials from these. AM conducted the in vitro experiments. MS and MC conducted the initial analysis and interpretation of the data. JA reanalysed some of the data and wrote the manuscript with input from the other authors, and in particular from AE and IM with respect to interpretation and perspectives.
###end p 91
###begin title 92
Acknowledgements
###end title 92
###begin p 93
We thank Julie Cakebread for her help in preparing the manuscript.
###end p 93
###begin article-title 94
###xml 44 50 <span type="species:ncbi:9606">humans</span>
Conjugated linoleic acid supplementation in humans-metabolic effects
###end article-title 94
###begin article-title 95
###xml 93 99 <span type="species:ncbi:9606">humans</span>
Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans
###end article-title 95
###begin article-title 96
###xml 64 70 <span type="species:ncbi:9606">humans</span>
Conjugated linoleic acid reduces body fat in healthy exercising humans
###end article-title 96
###begin article-title 97
###xml 71 77 <span type="species:ncbi:9606">humans</span>
Conjugated linoleic acid reduces body fat mass in overweight and obese humans
###end article-title 97
###begin article-title 98
The conjugated linoleic acid (CLA) isomer, t10c12-CLA, is inversely associated with changes in body weight and serum leptin in subjects with type 2 diabetes mellitus
###end article-title 98
###begin article-title 99
Conjugated linoleic acid and obesity control: efficacy and mechanisms
###end article-title 99
###begin article-title 100
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Conjugated linoleic acid rapidly reduces body fat content in mice without affecting energy intake
###end article-title 100
###begin article-title 101
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice
###end article-title 101
###begin article-title 102
Isomer-dependent metabolic effects of conjugated linoleic acid: insights from molecular markers sterol regulatory element-binding protein-1c and LXRalpha
###end article-title 102
###begin article-title 103
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
Dietary trans-10, cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse
###end article-title 103
###begin article-title 104
###xml 112 115 <span type="species:ncbi:9606">men</span>
Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome
###end article-title 104
###begin article-title 105
###xml 149 152 <span type="species:ncbi:9606">men</span>
Effects of cis-9, trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men
###end article-title 105
###begin article-title 106
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus
###end article-title 106
###begin article-title 107
###xml 109 115 <span type="species:ncbi:9606">humans</span>
Opposing effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid on blood lipids in healthy humans
###end article-title 107
###begin article-title 108
The effect of conjugated linoleic acid supplementation after weight loss on body weight regain, body composition, and resting metabolic rate in overweight subjects
###end article-title 108
###begin article-title 109
###xml 72 78 <span type="species:ncbi:9606">humans</span>
Safety profile of conjugated linoleic acid in a 12-month trial in obese humans
###end article-title 109
###begin article-title 110
###xml 119 124 <span type="species:ncbi:9606">human</span>
The effect of dietary supplementation using isomeric blends of conjugated linoleic acid on lipid metabolism in healthy human subjects
###end article-title 110
###begin article-title 111
###xml 106 109 <span type="species:ncbi:10116">rat</span>
Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat
###end article-title 111
###begin article-title 112
Isomer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression
###end article-title 112
###begin article-title 113
###xml 100 103 <span type="species:ncbi:10116">rat</span>
Isomer-specific actions of conjugated linoleic acid on muscle glucose transport in the obese Zucker rat
###end article-title 113
###begin article-title 114
###xml 141 145 <span type="species:ncbi:10116">rats</span>
Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats
###end article-title 114
###begin article-title 115
Species differences in the metabolism and regulation of gene expression by conjugated linoleic acid
###end article-title 115
###begin article-title 116
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity
###end article-title 116
###begin article-title 117
Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease
###end article-title 117
###begin article-title 118
###xml 75 80 <span type="species:ncbi:9606">human</span>
Isomer-specific regulation of metabolism and PPARgamma signaling by CLA in human preadipocytes
###end article-title 118
###begin article-title 119
Evidence that the anti-obesity effect of conjugated linoleic acid is independent of effects on stearoyl-CoA desaturase1 expression and enzyme activity
###end article-title 119
###begin article-title 120
Trans10, cis12-conjugated linoleic acid prevents triacylglycerol accumulation in adipocytes by acting as a PPARgamma modulator
###end article-title 120
###begin article-title 121
###xml 92 95 <span type="species:ncbi:10116">rat</span>
[Effect of conjugated linoleic acid on PPAR gamma gene expression and serum leptin in obese rat]
###end article-title 121
###begin article-title 122
trans-10, cis-12 CLA inhibits differentiation of 3T3-L1 adipocytes and decreases PPAR gamma expression
###end article-title 122
###begin article-title 123
###xml 127 131 <span type="species:ncbi:10090">mice</span>
Dietary conjugated linoleic acid reduces body fat mass and affects gene expression of proteins regulating energy metabolism in mice
###end article-title 123
###begin article-title 124
###xml 86 105 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
Modulation of body fat and serum leptin levels by dietary conjugated linoleic acid in Sprague-Dawley rats fed various fat-level diets
###end article-title 124
###begin article-title 125
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Conjugated linoleic acid reduces body fats and cytokine levels of mice
###end article-title 125
###begin article-title 126
Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPAR gamma-dependent mechanism
###end article-title 126
###begin article-title 127
###xml 104 106 104 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db</sup>
###xml 111 114 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">db </sup>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
Glycerides rich in conjugated linoleic acid (CLA) improve blood glucose control in diabetic C57BLKS-Leprdb/leprdb mice
###end article-title 127
###begin article-title 128
###xml 76 80 <span type="species:ncbi:10090">mice</span>
Trans-10, cis-12 CLA increases liver and decreases adipose tissue lipids in mice: possible roles of specific lipid metabolism genes
###end article-title 128
###begin article-title 129
###xml 92 103 <span type="species:ncbi:10116">Wistar rats</span>
Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y
###end article-title 129
###begin article-title 130
Use and abuse of HOMA modeling
###end article-title 130
###begin article-title 131
###xml 28 34 <span type="species:ncbi:9606">humans</span>
Conjugated linoleic acid in humans: regulation of adiposity and insulin sensitivity
###end article-title 131
###begin article-title 132
###xml 133 137 <span type="species:ncbi:10116">rats</span>
The thiazolidinedione insulin sensitiser, BRL 49653 increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats
###end article-title 132
###begin article-title 133
###xml 149 157 <span type="species:ncbi:9606">patients</span>
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes
###end article-title 133
###begin article-title 134
###xml 158 177 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats
###end article-title 134
###begin article-title 135
###xml 142 146 <span type="species:ncbi:10090">mice</span>
Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor alpha-null mice
###end article-title 135
###begin article-title 136
Adiponectin and resistin-new hormones of white adipose tissue
###end article-title 136

